Clinical Trial Update: CEND-1 in Combination with Neoadjuvant FOLFIRINOX with or Without Panitumumab [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update on a Phase 1/2 study of CEND-1 with neoadjuvant FOLFIRINOX, with or without panitumumab, in colon and pancreatic cancers.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colon Cancer
• Pancreatic Cancer

Drugs mentioned

• CEND-1
• FOLFIRINOX
• Panitumumab (panitumumab)

Snippet

Sponsor: Anup Kasi | Conditions: Colon Cancer, Pancreas Cancer | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING